Frontlight ResearchEarly access
TerminatedPhase 1
Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)
Key facts
- Who runs it
- Alfasigma S.p.A.
- Where
- France, Germany, Poland, Spain, and United Kingdom10 sites in 5 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 9 people enrolled
- Started
- 13 May 2024
- Ended
- 17 Jun 2026
- Type of study
- Interventional, 3 groups
- Treatments tested
- Filgotinib
- Record updated
- 15 July 2026
- Why it stopped
- The sponsor decided to stop recruitment and to early terminate the trial with 9 enrolled patients.
Who can take part
- Age
- 8 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Participant with a body mass index (BMI) within the 5th to 95th percentiles for the age and gender (based on World Health Organization BMI charts). Participant must have a minimum weight of 15 kg
- Participant must meet the International League of Associations for Rheumatology classification for 1 of the following categories and have, according to the investigator's judgment, moderately to severely active disease that is not adequately controlled with his/her current therapy; Rheumatoid factor (RF)-positive polyarthritis; RF-negative polyarthritis; Oligoarthritis; Psoriatic arthritis; Enthesis-related arthritis (ERA) Note: Historical Human leukocyte antigen B-27 (HLA-B27) results are considered appropriate for ERA diagnosis during screening; Systemic JIA with active arthritis without active systemic features, or with active systemic features that are stable in the prior 6 months of time of enrollment
- Participant with intolerance or a history of inadequate response to at least one of the following medications for the treatment of JIA, administered for at least 12 weeks, based on current treatment guidelines: conventional synthetic disease-modifying antirheumatic drugs and biological disease-modifying antirheumatic drugs (including methotrexate) and non-steroidal anti-inflammatory drugs for ERA and psoriatic arthritis
- Female participants of childbearing potential (i.e. who have passed menarche) must have a negative highly sensitive urine pregnancy test
Who cannot take part
- Currently on any therapy for chronic infection (such as pneumocystis, cytomegalovirus, herpes simplex, or atypical mycobacteria); Note: Other protocol defined Inclusion/ Exclusion criteria may apply
- Participant with any other any other rheumatic, inflammatory, or immunologic disease (e.g. inflammatory bowel disease, hypogammaglobulinemia, systemic lupus erythematosus, or uncontrolled uveitis)
- Active infection that is clinically significant, as per judgment of the investigator
- Participant with a history of complicated herpes zoster infection (with multi-dermatomal, disseminated, ophthalmic, or central nervous system involvement)
- Participant with persistent oligoarthritis
- Participant with undifferentiated arthritis
This trial has no sites in United States.
It has sites in 5 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Study to evaluate the pharmacokinetics, safety, and tolerability in paediatric population for treating juvenile idiopathic arthritis (JIA).
The 3 groups in the trial
- Filgotinib Dose ATreatment being tested
Dose A of filgotinib mini-tablet for participants with bodyweight (BW) 15-\<25 kg
Treatment: Filgotinib
- Filgotinib Dose BTreatment being tested
Dose B of filgotinib tablet for participants with BW ≥25-\<60 kg
Treatment: Filgotinib
- Filgotinib Dose CTreatment being tested
Dose C of filgotinib tablet for participants with BW ≥60 kg
Treatment: Filgotinib
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- An Open-label, Multiple Dose, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Filgotinib in Children and Adolescents From 8 to Less Than 18 Years of Age With Juvenile Idiopathic Arthritis
- Record updated
- 15 July 2026